m625 is not a clinical decision tool · not a publisher · not an expert authority · not a simulator. It is a cross-domain Roll-formalized evidence atlas with public audit + attack surface.
cross-domain transfer from chronic-pain / metabolic-disease research to "longevity" is often surface-form.
m625 does not advise on any specific longevity pipeline. **m625 shows that m516's intake-round-based evidence collection pattern is structurally compatible with the TMU-A cross-Δ same-V pattern from m517 CARD06 (VGAIT)**, and that any longevity claim should declare the K4.1 bit-pattern of its proposed evidence.
This is not an investment recommendation. This is not an affirmation of any longevity intervention. (See "What this demo will not say".)
The Roll-formalized object (anchored on m516 + m517 CARD06)
Field
Value
Upstream sources
m516 LongProof Longevity (intake rounds 1+2 active per W0 pre-flight) + m517 02_cards_cooked/CARD06_DEEP_v0.2.md (VGAIT cross-Δ same V pattern)
K4.1 = (0, 0, 0) to (0, 0, 1) depending on modality — viable-set should remain across Δ-B variations, which is the substantive longevity claim
Pattern
V (viable set) constant across different Δ (intervention modality) — per Kernel §3.2 and Framework §4.5
m516 status
2 active intake rounds; execution_kit present (training_data_recall · m516 readiness band per W0 pre-flight L1 disk)
Open issue inherited from m517 CARD06
I-002 VGAIT remote viability LOW · empirically open
How a VC evaluating longevity should read this evidence (≤ 5 minutes)
Cross-modality V invariance is the right framing. A longevity claim that depends on a specific intervention (single Δ-B) is by definition not a "longevity platform" claim — it is a "this specific modality" claim. The VGAIT pattern (m517 CARD06) is the Roll-formalized way to say: the same viable set V is reachable across multiple Δ-B paths.
m516 intake-round structure is the evidence-collection analog. Round 1 + round 2 active suggests m516 is building an evidence base in a structured intake pattern. A sponsor pitch that claims "longevity evidence" without disclosing a structured intake protocol is structurally weaker than m516's own approach.
K4.1 declaration is non-optional. Whether the longevity claim posits altered X (biomarker substrate), altered Φ (aging dynamics), or only altered Δ-B (intervention boundary) is the first thing a Roll-formalized longevity claim should declare. Pitches that skip this should be rejected.
Cross-domain transfer caveat. Transferability from m517 chronic-pain VGAIT to longevity is bit-pattern necessary, not substantive sufficient. The substrates (brain-network state vs. biological-age biomarkers) are categorically different. m620 has no longevity-specific exec dir yet (v0.3 target); a substantive transfer claim awaits that verification.
The VGAIT cross-Δ same-V pattern (m517 CARD06 · neuro chronic-pain) and m516 intake-round structure (longevity) share a structural invariance pattern — V invariant under Δ-B variation. transferability_pct: the bit-pattern is necessary, not sufficient, for cross-domain Roll transfer. Substantive cross-domain claims await m620 longevity-specific verification (v0.3 target). m625 does not assert any quantitative transferability score in v0.2.
What this demo will not say (anti-drift)
❌ It does not assert any specific longevity intervention works.
❌ It does not promise extended healthspan, restoration, or rejuvenation (cure/reverse lexicon, audit gate G2.2).
❌ It does not name or rank specific longevity sponsors / startups / supplements.
❌ It does not assert membership in K4.1 = (1, 1, 1)phi_direct_rewrite (that pattern belongs to in-vivo CD19 CAR-T per i_demo_003 — a longevity intervention does not jump into it without m620 verification).
❌ It does not project financial returns, market sizes, or pipeline valuations.
Falsifying prediction (per W6.5 + Roll EPP-3)
The cross-modality V invariance framing would be falsified by:
an m516 intake-round-2 verdict that fails to satisfy V invariance across the modalities studied — i.e., shows V is modality-specific in m516's own data; or
a m620 longevity-specific exec ladder (v0.3 target) returning a verdict < 70 on cross-modality transfer.
Both paths are open and depend on m516/m620 sovereign work.
待办: m620 longevity-specific exec dir (v0.3 target · m620-sovereign work); specific m516 intake-round-2 outcome cross-reference (deferred to v0.3 once m516 publishes round-2 outcome surface).
漏洞: m516 readiness band is training_data_recall · TODO_unverified; the structural-invariance framing assumes m516's intake pattern matches what's described — pending m516 v0.x publication. Cross-modality V invariance is asserted from m517 CARD06 but CARD06 itself has open issue I-002 (VGAIT remote viability LOW).
反驳预案:
- *"VCs want supplement names and dosages."* — m625 does not name supplements or dosages. That is per-modality work; m625 supplies the framework only.
- *"Why no rapamycin or NAD+ specifics?"* — Same. Specifics require sponsor-supplied K4.1 declaration; m625 does not invent them.
- *"What if no longevity intervention has cross-modality V invariance?"* — Then the framework correctly says no longevity pipeline has demonstrated platform-level transfer. That is honest.